In AML treated with induction chemotherapy, the XPC Ala499Val SNP was associated with lower overall disease-free survival, particularly when combined with an XPD codon 751 AC/CC polymorphism (78), and two XPC SNPs (Ala499Val and Lys939Gln) were associated with variable responses to imatinib in BCR-ABL driven chronic myelogenous leukemia (CML) (79). This evidence concerns the gene XPC and acute myeloid leukemia.